The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence

• Laura Poliseno ,

  Contributed equally to this work with: Laura Poliseno, Letizia Pitto

  Affiliations Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy, Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Letizia Pitto ,

  Contributed equally to this work with: Laura Poliseno, Letizia Pitto

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Marcella Simili,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Laura Mariani,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Luisa Riccardi,

  Affiliations Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Alessia Ciucci,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Milena Rizzo,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Monica Evangelista,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Alberto Mercatanti,

  Affiliation Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy

  ⨯
• Pier Paolo Pandolfi,

  Affiliations Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Giuseppe Rainaldi

  * E-mail: g.rainaldi@ifc.cnr.it

  Affiliations Laboratory of Gene and Molecular Therapy, Institute of Clinical Physiology, CNR, Pisa, Italy, Istituto Toscano Tumori, Firenze, Italy

  ⨯